Cytokinetics (CYTK) – Analysts’ Recent Ratings Updates

Cytokinetics (NASDAQ: CYTK) has recently received a number of price target changes and ratings updates:

• 5/14/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
• 5/13/2025 – Cytokinetics was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.
• 5/8/2025 – Cytokinetics had its price target lowered by analysts at Barclays PLC from $55.00 to $53.00. They now have an “overweight” rating on the stock.
• 5/7/2025 – Cytokinetics had its price target lowered by analysts at Royal Bank of Canada from $82.00 to $80.00. They now have an “outperform” rating on the stock.
• 5/7/2025 – Cytokinetics had its price target lowered by analysts at Citigroup Inc. from $86.00 to $80.00. They now have a “buy” rating on the stock.
• 5/2/2025 – Cytokinetics had its price target lowered by analysts at UBS Group AG from $47.00 to $41.00. They now have a “neutral” rating on the stock.
• 5/2/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
• 4/24/2025 – Cytokinetics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $55.00 price target on the stock.
• 4/21/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
• 4/15/2025 – Cytokinetics had its price target lowered by analysts at Bank of America Co. from $62.00 to $54.00. They now have a “neutral” rating on the stock.
• 4/15/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
• 4/10/2025 – Cytokinetics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $78.00 price target on the stock.
• 4/8/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
• 4/4/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.

Cytokinetics Stock Down 0.0%

Shares of NASDAQ:CYTK traded down $0.01 during trading on Tuesday, hitting $30.53. 1,887,989 shares of the company’s stock traded hands, compared to its average volume of 1,621,552. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The company has a 50-day moving average price of $37.32 and a 200-day moving average price of $44.22. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $61.38. The company has a market cap of $3.65 billion, a price-to-earnings ratio of -5.67 and a beta of 0.81.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.05. The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.77 million. The business’s quarterly revenue was up 89.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.33) earnings per share. As a group, research analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Insider Buying and Selling

In other Cytokinetics news, Director Muna Bhanji sold 1,454 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $29.73, for a total transaction of $43,227.42. Following the completion of the transaction, the director now owns 23,510 shares in the company, valued at approximately $698,952.30. This represents a 5.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Andrew Callos sold 4,002 shares of Cytokinetics stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $36.68, for a total value of $146,793.36. Following the completion of the sale, the executive vice president now directly owns 60,687 shares in the company, valued at $2,225,999.16. This represents a 6.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 94,816 shares of company stock worth $3,850,385 over the last ninety days. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors have recently bought and sold shares of the company. Fifth Third Bancorp grew its stake in shares of Cytokinetics by 42.2% during the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 291 shares in the last quarter. State of Michigan Retirement System boosted its holdings in Cytokinetics by 1.1% during the first quarter. State of Michigan Retirement System now owns 28,200 shares of the biopharmaceutical company’s stock worth $1,133,000 after purchasing an additional 300 shares during the last quarter. Louisiana State Employees Retirement System grew its position in Cytokinetics by 0.9% in the first quarter. Louisiana State Employees Retirement System now owns 33,100 shares of the biopharmaceutical company’s stock valued at $1,330,000 after purchasing an additional 300 shares in the last quarter. State of Alaska Department of Revenue increased its stake in Cytokinetics by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 13,820 shares of the biopharmaceutical company’s stock valued at $555,000 after buying an additional 365 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in shares of Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 374 shares during the last quarter.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.